Milestone for Crispr: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial |
Milestone for Crispr: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial
A biotech company is looking to get approval next after their recent discovery.
BY MOSES JEANFRANCOIS, NEWS WRITER @MOSESJEANS
Illustration: Getty Images
The future of medicine is already here. Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling condition has succeeded in a Phase 3 trial, marking a major milestone for the technology.
The gene-editing treatment allows scientists to edit, insert, or remove DNA sequences in living organisms using a guide RNA. In the recent trial from Intellia, the company used CRISPR to turn off the gene that contributes to hereditary........